J Biol Chem, Vol. 275, Issue 3, 1656-1664, January 21, 2000
Human Complement 5a (C5a) Anaphylatoxin Receptor (CD88)
Phosphorylation Sites and Their Specific Role in Receptor
Phosphorylation and Attenuation of G Protein-mediated Responses
DESENSITIZATION OF C5a RECEPTOR CONTROLS SUPEROXIDE PRODUCTION
BUT NOT RECEPTOR SEQUESTRATION IN HL-60 CELLS*
Thierry
Christophe
,
Marie-Josèphe
Rabiet,
Marianne
Tardif,
Marie-Danielle
Milcent, and
François
Boulay§
From the Commissariat à l'Energie Atomique, Grenoble,
Départment de Biologie Moléculaire et Structurale,
Laboratoire de Biochimie et de Biophysique des Systèmes
Intégrés, Unité Mixte de Recherche 314 Commissariat
à l'Energie Atomique, CNRS, 17 rue des Martyrs, 38054 Grenoble
Cedex 9, France
 |
ABSTRACT |
Upon agonist binding, the anaphylatoxin human
complement 5a receptor (C5aR) has previously been found to be
phosphorylated on the six serine residues of its carboxyl-terminal tail
(Giannini, E., Brouchon, L., and Boulay, F. (1995) J. Biol.
Chem. 270, 19166-19172). To evaluate the precise roles that
specific phosphorylation sites may play in receptor signaling, a series
of mutants were expressed transiently in COS-7 cells and stably in the
physiologically relevant myeloid HL-60 cells. Ser334 was
found to be a key residue that controls receptor phosphorylation. Phosphorylation of either of two serine pairs, namely
Ser332 and Ser334 or Ser334 and
Ser338, was critical for the phosphorylation of C5aR and
its subsequent desensitization. Full phosphorylation and
desensitization of C5aR were obtained when these serines were replaced
by aspartic acid residues. The mutation S338A had no marked effect on
the agonist-mediated phosphorylation of C5aR, but it allowed a
sustained C5a-evoked calcium mobilization in HL-60 cells. These
findings and the ability of the S314A/S317A/S327A/S332A mutant receptor
to undergo desensitization indicate that the phosphorylation of
Ser334 and Ser338 is critical and sufficient
for C5aR desensitization. The lack of phosphorylation was found to
result not only in a sustained calcium mobilization and extracellular
signal-regulated kinase 2 activity but also in the enhancement of the
C5a-mediated respiratory burst in neutrophil-like HL-60 cells. For
instance, the nonphosphorylatable S332A/S334A mutant receptor triggered
a 1.8-2-fold higher production of superoxide as compared with the
wild-type receptor. Interestingly, although the desensitization of this
mutant was defective, it was sequestered with the same time course and
the same efficiency as the wild-type receptor. Thus, in myeloid HL-60
cells, desensitization and sequestration of C5aR appear to occur
through divergent molecular mechanisms.
 |
INTRODUCTION |
The capacity of phagocytic leukocytes to clear the host from
invading microorganisms is dependent on their ability to migrate to
sites of inflammation and to release large amounts of proteolytic enzymes and reactive oxygen species. Phagocytes do this in response to
a variety of structurally diverse chemoattractants, including bacterial
N-formylated peptides, the complement fragment
C5a,1 leukotriene B4,
platelet-activating factor, and interleukin 8 (reviewed in Ref. 1).
Chemoattractants elicit intracellular signaling through specific
receptors that are coupled to the pertussis toxin-sensitive
heterotrimeric Gi2 protein. This latter activates in turn
second messenger-generating enzymes, including phospholipases C, D, and
A2 (reviewed in Ref. 2), as well as kinases, such as
phosphatidylinositol 3-kinase (3) and sphingosine kinase (4).
Ultimately, the NADPH-oxidase is activated and releases superoxide
anions. This is a crucial bactericidal mechanism, but it is also
believed to be a major cause of inflammatory disorders when
inappropriately activated.
The activation of the NADPH-oxidase complex responsible for the
production of superoxide requires the coordinated action of multiple
signaling pathways. The NADPH-oxidase becomes functional through a
multistep assembly of several components at the plasma membrane, namely
the flavocytochrome b558, the small G proteins (Rac and Rap), and cytosolic factors (p47phox, p67phox,
and p40phox) (reviewed in Ref. 5). The ability of
chemoattractants to induce the production of superoxide varies from one
chemoattractant to another. The activation of the NADPH-oxidase complex
is correlated with the rapid increase in Ca2+ and
diacylglycerol, which subsequently activate protein kinase C (PKC), and
the phosphorylation of the cytosolic factor p47phox (6, 7). The
involvement of PKC in triggering the activation of NADPH oxidase is
supported by the ability of phorbol 12-myristate 13-acetate (PMA) to
induce a sustained superoxide production and the phosphorylation and
translocation of p47phox to the plasma membrane (8).
Despite the persistent presence of chemoattractants, the intracellular
signaling events are transient, with a time course in the minute range.
This attenuated responsiveness is thought to result from the
desensitization of receptors through their phosphorylation and rapid
sequestration (reviewed in Refs. 9 and 10). The current concept for
desensitization of G protein-coupled receptors (GPCRs), largely
extrapolated from numerous studies with rhodopsin and the
2-adrenergic receptor, is that arrestin proteins bind to the
phosphorylated receptors and sterically prevent its interaction with
the G protein (11-13). In addition,
-arrestin acts as a clathrin
adapter that targets the agonist-occupied
2-adrenergic receptor to
the endocytic pathway via clathrin coated pits (14, 15). Expression of
a GTPase defective dynamin mutant (K44A) (16) specifically inhibits the
clathrin-dependent endocytic pathway and the
agonist-mediated internalization of GPCRs is inhibited. However,
mounting evidence indicates that not all GPCRs are internalized through
this pathway. For instance, internalization of the angiotensin II 1A
and m2 muscarinic acetylcholine receptors in HEK293 cells is
independent of
-arrestin and is not inhibited when the
clathrin-coated vesicle pathway is blocked by overexpression of a
dominant negative form of dynamin (17-19).
Although receptor desensitization is thought to be a key regulatory
mechanism controlling the inflammatory potential of phagocytic cells,
the impact of an altered chemoattractant receptor desensitization on
intracellular signaling events and the release of reactive oxygen
species has never been investigated in leukocytes. The C5a receptor
(C5aR) is particularly well suited to examine this issue because
previous studies have shown the rapid agonist-mediated phosphorylation
of this receptor on serine residues in differentiated HL-60 cells and
after heterologous expression (20-22). In transfected COS-7 cells, the
six serine residues of the carboxyl-terminal domain, at positions 314, 317, 327, 332, 334, and 338, were identified as the major
phosphorylation sites, but it is not known whether a stoichiometry of 6 phosphate groups per receptor is required for receptor desensitization
(22).
In this paper, we show that phosphorylation of either of the two serine
pairs (Ser332/Ser334 and
Ser334/Ser338) is a prerequisite for full
receptor phosphorylation. This strongly supports the notion that C5aR
is sequentially phosphorylated upon agonist binding. However,
phosphorylation of the first four serine residues was found to be
dispensable for receptor desensitization. In stably transfected HL-60
cells, receptor sequestration was found to be independent of receptor
desensitization. In addition, the results show for the first time that
a nonphosphorylatable receptor is able to support sustained
intracellular signaling events that result in a significant increase in
the production of superoxide by neutrophil-like differentiated HL-60
cells. This indicates that cell adaptation to a persistent stimulus is
to some extent dependent on receptor phosphorylation.
 |
EXPERIMENTAL PROCEDURES |
Materials--
PMA, N-formyl-Met-Leu-Phe-Lys-OH
(fMLFK), N6,O-2'-dibutyryl adenosine
3',5' cyclic monophosphate (Bt2cAMP), human recombinant C5a, bovine serum albumin, myelin basic protein, leupeptin,
benzamidine, pepstatin, aprotinin, phenylmethylsulfonyl fluoride,
p-nitrophenylphosphate, pertussis toxin, cytochrome
c, and phosphate-free RPMI medium were obtained from Sigma
Chemical Co. Restriction enzymes and 4-(2-aminoethyl)-benzenesulfonyl
fluoride hydrochloride were from Roche Molecular Biochemicals. Protein
A-Sepharose was purchased from Amersham Pharmacia Biotech. Cell culture
media, fetal calf serum, and Geneticin (G418) were from Life
Technologies, Inc. [32P]Orthophosphoric acid and
Na125I were purchased from Amersham Pharmacia Biotech.
Cell Culture and Differentiation--
Promyelocytic HL-60 cells
and COS-7 cells were cultured in RPMI 1640 medium and Dulbecco's
modified Eagle's medium with GlutaMAX I, respectively. Differentiation
of HL-60 cells was initiated with 1 mM Bt2cAMP
for 3 days as described (23).
Oligonucleotide-directed Mutagenesis--
To construct serine to
alanine replacement mutants, the cDNA encoding wild-type C5aR was
excised from the pCDM8-C5aR plasmid with HindIII and
BamHI and subcloned into pSELECT-1 vector to generate a
single-stranded DNA. The Promega pSELECT-1 mutagenesis protocol was
followed to carry out mutagenesis reactions. The mutated cDNAs were
excised from pSELECT-1 with HindIII and BstEII and subcloned into pCDNA3.1-C5aR after digestion with
HindIII and BstEII. Mutagenesis used to generate
serine to aspartic acid replacement mutants was performed on
pCDNA3.1-C5aR with the QuickChange method of Stratagene, Inc,
according to the manufacturer's instructions. Coding sequences of all
mutated cDNAs were verified by sequencing.
Transfection of Cells--
COS-7 cells were transiently
transfected by electroporation with wild-type or mutant C5aR in the
pCDNA3.1 expression vector as described previously (24). Thirty
millimeter plates were seeded with 3 × 105
electroporated cells. After 60-72 h, cells were used for either metabolic labeling with [32P]orthophosphoric acid or
125I-labeled C5a binding. The pEFneo expression plasmid
(25) was used to stably express mutant C5aR in HL-60 cells as described previously (23). For each clone of HL-60 transformant, receptor expression was assessed by 125I-labeled C5a binding. A
level of surface expression ranging from 25,000 to 35,000 receptors per
cell was found for wild-type and most mutant receptors, except the
S332A/S334A/S338A mutant receptor, for which the level of expression
did not exceed 10,000 receptors per cell. For all mutant receptors the
affinity for 125I-labeled C5a was similar to that found
with the wild-type receptor (KD ~ 10 nM) (data not shown).
Radioligand Binding Assays--
125I-labeled C5a was
prepared by the chloramine T method (22). All binding studies were
carried out at 4 °C with subconfluent COS-7 cell monolayers 3 days
after transfection or with stably transfected HL-60 as described
(26).
Metabolic Labeling and Immunoprecipitation--
Transiently
transfected COS-7 cells were metabolically labeled with
[32P]orthophosphoric acid (0.3-0.5 mCi/ml), and
phosphorylated C5aR was immunoprecipitated as described (22). To be
able to compare the level of phosphorylation of the different mutants,
the volume of cell lysates withdrawn for immunoprecipitation was
adjusted to immunoprecipitate the same amount of surface-expressed receptors.
Cytosolic Ca2+ Measurements--
HL-60 cells were
washed with phosphate-buffered saline, resuspended at a density of
2 × 107 cells/ml in RPMI medium with 0.1% bovine
serum albumin and without phenol red. Cells were loaded with 2 µM Fura-2/AM for 30 min, at 37 °C and then diluted in
2 volumes of RPMI medium without bovine serum albumin and centrifuged.
Cell pellets were washed once with Krebs-Ringer phosphate buffer
supplemented with 1.2 mM CaCl2, 5 mM NaHCO3, and 20 mM Hepes at pH
7.5 (KRG buffer). Cells were then resuspended in RPMI medium without
phenol red, at a density of 2 × 107 cells/ml. Calcium
measurements were performed on 5 × 106 cells in KRG
buffer with a SPEX FluoroMAX fluorescence spectrophotometer with an
excitation wavelength of 340 nm, an emission wavelength of 505 nm, and
slit widths of 5 and 10 nm, respectively. In the presence of
extracellular calcium, maximal and minimal fluorescence levels were
determined in the presence of 0,04% Triton X-100 followed by the
addition of 5 mM EGTA plus 30 mM Tris-HCl, pH
7.4, respectively. For measurement of intracellular calcium
mobilization in the absence of extracellular calcium, 1 mM
EGTA was added into the cuvette before the addition of C5a in order to
complex extracellular calcium. Minimal fluorescence was determined as
above, and maximal fluorescence was then measured by adding a
saturating concentration of CaCl2. Intracellular free
calcium concentrations were calculated using the following formula:
[Ca2+]i = KD
(F
Fmin)/(Fmax
F), where KD = 224 nM.
Immunoprecipitation of Erk2 and Immunocomplex Erk2 Activity
Assay--
Differentiated HL-60 cells were resuspended in RPMI medium
(33 × 107 cells/ml). Six hundred microliters of cell
suspension were treated with C5a (25 nM) for various
periods of time. Erk2 was immunoprecipitated and kinase activity was
assayed as described previously (23). Aliquots corresponding to
of washed complexes were kept for Western blot analysis of
immunoprecipitated MAP kinase. For Western blot, the first antibody was
the same as that used during the immunoprecipitation step (dilution,
1:1000), and detection of MAP kinase was performed with
125I-labeled protein A.
Superoxide Production Assay--
Differentiated HL-60 cells
expressing either wild-type or mutant C5aR were washed with
phosphate-buffered saline and resuspended at a concentration of 4 × 107 cells/ml in phosphate-buffered saline containing 0.5 mM CaCl2, 1 mM MgCl2,
and 30 mM glucose (Buffer A). Fifty microliters of the cell
suspension, kept at 15 °C, were added to 1 ml of prewarmed Buffer A
containing 200 µM of ferricytochrome c.
Maximal superoxide production was determined in the presence of fMLFK
(10 nM) plus PMA (1 µg/ml) (23). Ferricytochrome
c reduction was continuously monitored at 550 nm.
Receptor Internalization--
Internalization of C5aR was
evaluated as the intracellular accumulation of 125I-labeled
C5a as follows. C5aR-transfected HL-60 cells were centrifuged and
washed once in phosphate-buffered saline and resuspended at a density
of 3 × 107 cells/ml in ice-cold KRG buffer. Surface
expressed receptors were saturated with 125I-labeled C5a
(100 nM) for 60 min, at 4 °C. Control cells were incubated on ice with an excess of unlabeled C5a to determine nonspecific binding. Internalization was initiated by diluting cells in
10 volumes of KRG buffer at 37 °C. At various time points, aliquots
(6 × 106 cells) were withdrawn and added to 5 volumes
of ice-cold buffer containing 0.15 M NaCl and 0.2 M acetic acid at pH 2.5 for 10 min on ice. This incubation
removes 125I-labeled C5a bound to cell surface but has no
effect on ligand internalized into cells. After centrifugation, cell
pellets were resuspended in 0.5 ml of ice-cold acid buffer and loaded
on a cushion of ice-cold KRG buffer (0.5 ml) containing 8% sucrose to
separate free ligand from cell-associated ligand. Results are expressed
as the percentage of saturably bound 125I-labeled C5a that
is internalized as follows: (cpm resistant to acid wash after
warming
cpm resistant to acid wash before warming)/(cpm
specifically bound at 4 °C under saturating conditions).
Statistics--
Statistical significance was analyzed by
Student's t test.
 |
RESULTS |
Sequential Phosphorylation of the C5aR--
Mutants with
individual or combined amino acid replacements were constructed (Fig.
1), and their ability to be phosphorylated was assayed after transient expression in COS-7 cells. Agonist-induced phosphorylation of exogenous C5aR was not systematically assayed in
stably transfected HL-60 cells because an important variability was
observed in this system, most likely due to a much lower expression level in these cells. In order to immunoprecipitate the same amount of
receptor, the amount of surface-expressed receptors was titrated in
companion plates. The agonist-induced phosphorylation of C5aR was not
markedly reduced by the mutation S327A, S332A, or S338A (Fig.
2A). This reduction was consistent
with the disappearance of a single phosphorylation site. In contrast,
the replacement of Ser334 by an alanine severely reduced
the level of agonist-dependent phosphorylation (50-60%
reduction), suggesting that phosphorylation of Ser334 is a
key step in a sequential process.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 1.
Schematic representation of point mutations
in the carboxyl-terminal domain of C5aR. WT, wild-type.
Mutation positions are shown at the left with the single-letter code of
the replacement amino acid.
|
|

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 2.
C5a-induced phosphorylation of wild-type and
mutant C5aRs in COS-7 cells. Cells were transfected by
electroporation with wild-type (WT) or mutant (denoted by
single-letter code and position number) C5aR cDNAs in pcDNA3.1
or CDM8. Three days after transfection, cells were loaded with
[32P]orthophosphoric acid and treated with or without 50 nM C5a for 15 min, at 37 °C. After lysis, C5aR was
immunoprecipitated as described under "Experimental Procedures." To
ensure that equal amounts of receptor were loaded onto each lane, the
number of surface-expressed C5aRs was determined in companion plates,
and the volume of cell lysate treated for C5aR immunoprecipitation was
accordingly adjusted. Immunoprecipitated material was analyzed by 10%
SDS-polyacrylamide gel electrophoresis under reducing conditions
followed by autoradiography or PhosphorImager analysis for
quantification. Results are representative of at least two independent
experiments.
|
|
The reduction of phosphorylation induced by the mutation S334A was
strongly reinforced by a serine to alanine replacement either at
position 332 or at position 338. Indeed, whereas the single point
mutation S332A or S338A resulted only in a weak reduction of the
agonist-induced phosphorylation, combined mutations at positions 332 and 334, at positions 334 and 338, or at all three positions yielded
mutants exhibiting a very weak capacity to incorporate radioactive
phosphate in response to C5a binding (about 10% compared with
wild-type C5aR) (Fig. 2B). Interestingly, the
S314A/S317A/S327A/S332A mutant receptor was phosphorylated. The low
level of phosphate incorporation in this mutant is most likely due to
the existence of only two potential phosphoacceptor sites at positions
334 and 338 (Fig. 2B, right lane).
The poor ability of the double mutants S332A/S334A and S334A/S338A and
the triple mutant S332A/S334A/S338A to be phosphorylated prompted us to
examine whether aspartic acid residues at these positions would yield
mutants with a restored capacity to be phosphorylated. Judging by the
level of radioactivity incorporated in the S332D/S334D and
S332D/S334D/S338D mutant receptors, negative charges at these positions
are required to confer to C5aR the ability to be fully phosphorylated
(Fig. 2C).
As shown in Fig. 2A, the basal phosphorylation of S334A was
completely abolished, whereas that of S332A was reduced by about 50%.
Likewise, the S332D/S334D mutant receptor showed absolutely no
phosphate incorporation in the absence of agonist, providing further
support to the idea that Ser332 and Ser334 may
be accessible to kinase(s) when the receptor is in a resting state. To
test whether the basal phosphorylation of C5aR takes place at the
plasma membrane or occurs during the transport to the plasma membrane,
metabolic labeling was performed after inhibition of protein synthesis
with cycloheximide. As a basal phosphorylation was still observed (not
shown), it is likely that Ser332 and Ser334 are
phosphorylated after C5aR has reached the plasma membrane. In the
absence of C5a, surface-expressed receptors may wobble between a
resting state and a conformation that allows the exposure and the
phosphorylation of these two serine residues by cytoplasmic kinase(s).
However, the low level of radioactive phosphate incorporated during the
metabolic labeling with [32P]orthophosphoric acid
suggests that only a small fraction of surface-expressed receptors
undergoes such a conformational change. Alternatively, the low
basal incorporation of radioactive phosphate may result from the fact
that C5aR is already phosphorylated. Consequently, the incorporation of
radioactive phosphate is limited by the rate of
phosphorylation/dephosphorylation of C5aR in the absence of agonist.
Although a constitutive phosphorylation is speculative, it is clear
from the present results that the presence of negative charges at
positions 332 and 334 favors the C5a-mediated phosphorylation process.
Altogether, the results indicate that Ser334 and probably
Ser332 are the most accessible phosphoacceptor groups and
that the agonist-mediated phosphorylation of C5aR is sequential.
Phosphorylation of Ser314, Ser317, and
Ser327 requires the presence of either phosphoseryl
residues or aspartic acid residues at positions 332 and 334 or
positions 334 and 338.
Phosphorylation of Key Serine Residues Is Sufficient for C5aR
Desensitization--
If specific phosphorylation sites are important
for the desensitization process, one would predict that their mutation
into alanine should result in prolonged intracellular signaling events. Conversely, when a wild-type phenotype is observed when only a few
serine residues are conserved, one can predict that these serine
residues play a key role in the desensitization process. In order to
evaluate the precise roles that specific phosphorylation sites may play
in signal transduction, we stably expressed wild-type and mutant
receptors in promyelocytic HL-60 cells, a myeloid cell line of
physiological relevance that does not express the C5aR unless
differentiated into neutrophil-like cells. To exclude clonal artifacts,
C5a-induced calcium mobilization was analyzed with at least three
independent clones of wild-type or mutant receptor-expressing cells.
To evaluate the functionality of wild-type and mutant C5aRs after
expression in HL-60 cells, we examined their ability to mobilize
intracellular calcium in the presence of extracellular calcium (Fig.
3A). Cells transfected with
wild-type C5aR showed an increase of intracellular calcium that peaked
within 8-10 s of the onset of C5a application. Intracellular calcium
returned to basal level in approximately 40 s. Mutant receptors
triggered a similar calcium response but for several of them the
kinetics of return to basal calcium level was slower than that with the wild-type C5aR. Thus, none of the amino acid replacements impaired the
coupling with the G protein.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 3.
C5a-evoked intracellular calcium mobilization
in HL-60 cells transfected with wild-type or mutant C5aRs.
Transfected HL-60 cells were loaded with Fura-2, and calcium
mobilization was assayed in the presence of extracellular
calcium after addition of a saturating dose of C5a (12.5 nM). A, representative traces of calcium
mobilization for each mutant (solid line) compared with the
wild-type receptor (dotted line). Mutations are denoted by
single-letter code and position number. B, a detailed
kinetic analysis was performed on at least three independent clones
expressing either wild-type C5aR or different mutant receptors
(n 3 for each clone). The calcium decays from 80%
of the peak height to basal calcium level could be fitted to an
exponential
(A·(e t/ ) + B). The data shown represent the mean ± S.E.
(n 9) time constant for the return of
intracellular free calcium concentration to basal level after C5a
stimulation. *, p < 0.001 as compared with cells
expressing exogenous wild-type C5aR.
|
|
The kinetics of decay to basal calcium level could be fitted to a
single exponential, which allowed us to define a time constant for
calcium decay (see legend to Fig. 3B). The mutants S332A, S334A, S314A/S317A, S314A/S317A/S327A/S332A, S332D/S334D, and S332D/S334D/S338D were found to have a time constant that was, on
average, similar to that of the wild-type C5aR (Fig. 3B). In contrast, the mutants S332A/S334A, S334A/S338A, and S332A/S334A/S338A were characterized by a time constant that was 3-4-fold higher, which
was consistent with the incapacity of these latter to be phosphorylated. Interestingly, although the S338A mutant receptor exhibited a robust phosphorylation in both COS-7 cells (Fig.
2A) and HL-60 cells (not shown), it had the ability to
induce a sustained calcium response. The time constant for calcium
decay with this mutant was about 4-fold higher than that with
wild-type C5aR (Fig. 3B).
Two mutants, namely S338A and S332A/S334A, were further analyzed with
respect to the activation of the MAP kinase pathway in HL-60 cells. In
neutrophils, C5a is known to activate the MAP kinase pathway through
the activation of Gi2 (27). Whereas in wild-type
C5aR-expressing cells, Erk2 activity returned to basal level within
90-120 s after the application of C5a, a sustained activation of Erk2
was observed in cells transfected with the nonphosphorylated
S332A/S334A mutant receptor (Fig. 4). Erk2
activity was still half-maximal 180 s after C5a application on
S332A/S334A receptor-expressing cells. A sustained activation of Erk2
was also found with the S334A/S338A receptors (not shown). Although the
S338A mutant receptor demonstrated a defective desensitization of the
C5a-induced calcium response, the effect on the activation of Erk2
remained modest, with a return to basal level of Erk2 activity within
180 s (see Fig. 4).

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 4.
Time course of C5a-induced activation of MAP
kinase. After stimulation with 25 nM C5a for various
periods of time, the Erk2 isoform was immunoprecipitated from lysates
of HL-60 cells expressing either wild-type (WT), S338A
(A338), or S332A/S334A (A332-334) C5aR. Western
blot analyses were systematically performed to check that the same
amount of kinase has been immunoprecipitated (data not shown). The
myelin basic protein (MBP) phosphorylation assay was
conducted as described under "Experimental Procedures." The figure
is representative of two independent experiments.
|
|
Thus, altogether, the results clearly indicate that the desensitization
of C5aR is a phosphorylation-dependent process. However, although C5aR is potentially phosphorylated on the six serine residues
of its carboxyl-terminal tail (22), a stoichiometry of 6 phosphoserine
residues per mole of receptor is not required for the attenuation of
signal transduction. The observation that the mutation S338A yields a
mutant with a reduced ability to desensitize the C5a-mediated calcium
response despite a strong capacity to be phosphorylated suggests that
Ser338 plays an important role in agonist-induced
desensitization of the C5aR.
Effect of Receptor Phosphorylation on Superoxide
Production--
We next asked whether a receptor deficient in its
ability to desensitize had an effect on a distal cellular response,
such as the generation of superoxide anions, which is also known as the
respiratory burst. To accomplish this, HL-60 cells were differentiated into neutrophil-like cells with dibutyryl cyclic AMP. After
differentiation, transfected cells expressed endogenous receptors for
C5a as well as exogenous wild-type or mutant C5aR. Differentiated cells
expressed around 40,000-50,000 receptors per cell, but the proportion
of mutant receptors was uncertain because the level of expression of
exogenous receptors may be altered in differentiated cells.
Using S338A and S332A/S334A C5aR-expressing cells, we first examined
whether exogenous mutant still conferred a mutant phenotype with
respect to calcium mobilization in the presence of extracellular calcium. For each type of HL-60 transformants, i.e.
expressing wild-type, S338A or S332A/S334A C5aR, three independent
clones were analyzed to avoid clonal artifacts. The mean values ± S.E. of agonist-elicited calcium mobilization are shown in Fig.
5A. In the presence of
extracellular calcium, the S338A receptors reproducibly exhibited a
sustained calcium response for about 30 s, followed by a rapid
decay to basal calcium level. Thus, in differentiated HL-60 cells, the
S338A receptors appears to have a mutant phenotype for only a short
period of time and then becomes desensitized as a wild-type receptor.
In the presence of extracellular calcium, the S332A/S334A mutant
receptor demonstrated a more sustained calcium response than the
wild-type receptor. The duration (measured at half-maximal response
after C5a addition) for wild-type and S332A/S334A mutant receptors was
around 50 and 150 s, respectively (Fig. 5A). In
contrast, in the absence of extracellular calcium, the mean duration of
calcium elevation was around 25 s with no significant difference
between the response mediated by the mutant and that mediated by the
wild-type receptor (Fig. 5B).

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 5.
Kinetics of C5a-evoked intracellular calcium
mobilization in differentiated HL-60 cells expressing either wild-type
or mutant C5aR. Bt2cAMP-differentiated HL-60 cells
were loaded with Fura-2, and calcium mobilization was assayed after
addition of a saturating concentration of C5a (12.5 nM).
A, mean responses ± S.E. (n 3, for
each clone) with three independent clones expressing either S332A/S334A
C5aR (A332-334), wild-type C5aR (WT), or S338A
C5aR (A338) (for the sake of clarity, only the mean response
is shown for S338A C5aR) in the presence of extracellular calcium.
B, mean responses ± S.E. (n 2) with
three independent clones expressing either wild-type C5aR or
S332A/S334A C5aR in the absence of extracellular calcium.
|
|
To examine whether the S332A/S334A mutant receptor had a higher
capacity than the wild-type receptor to trigger superoxide release, we
measured the C5a-evoked superoxide response of each HL-60 transformant
in the presence or absence of extracellular calcium. For each
transformant the maximal superoxide release was achieved by
costimulating cells with PMA and fMLFK as described previously (23).
The ratio between C5a-induced and maximal superoxide responses is
indicative of the ability of C5aRs to trigger the respiratory burst in
the different HL-60 transformants. It takes into account possible
variations in cell counts and in the amount of functional NADPH-oxidase
complex expressed in the different preparations of differentiated HL-60
cells. As illustrated by the dose-response curves shown in Fig.
6, in the presence of extracellular calcium,
the activation of the S332A/S334A mutant receptor stimulated a robust
superoxide release that was about 1.8-2-fold higher than that
following activation of wild-type C5aR-expressing cells. The S338A
mutant receptor triggered an oxidative response similar to that yielded
by the wild-type receptor (not shown). In the absence of extracellular
calcium, the C5a-induced superoxide response was reduced by about
60-70%, whereas the maximal response, i.e. in the presence
of PMA and N-formyl peptide, was not affected. This
reduction is consistent with previous studies indicating that calcium
influx is required for a maximal chemoattractant-induced superoxide
generation (28, 29). In the absence of extracellular calcium, the
C5a-evoked calcium responses by wild-type and S332A/S334A mutant
receptors were very similar, but more superoxide was still released by
S332A/S334A C5aR-expressing cells (Fig. 6).

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 6.
Dose-response curves of C5a-induced
superoxide production by differentiated HL-60 transformants.
Superoxide production was assayed as described under "Experimental
Procedures." Three independent clones expressing either the wild-type
(WT) C5aR (solid line) or the S332A/S334A
(A332-334) mutant receptor (dotted line) were
stimulated with different concentrations of C5a (n 3 for each clone). Results are presented as the mean ± S.E. ratio
between the C5a-induced superoxide production and the maximal
superoxide production induced by PMA plus fMLFK during 5 min in the
presence or absence of extracellular calcium.
|
|
Altogether, the results suggest that a defect in chemoattractant
receptor desensitization can enhance the production of reactive oxygen
species by neutrophil granulocytes.
Sequestration of C5aR in HL-60 Cells Is Independent of Its
Desensitization--
The heterologous expression of
phosphorylation-deficient mutants of C5aR in pancreatic
cells has
revealed that the agonist-mediated internalization of C5aR is
facilitated by the phosphorylation of its carboxyl-terminal tail (30).
Expression of mutants, truncated after Ser327 or
Ser334, in the rat basophilic RBL2H3 cell line has
indicated that the carboxyl-terminal tail of C5aR is required for
normal ligand dependent receptor internalization (31). However, the
mechanisms of internalization may vary from cell to cell depending on
the relative abundance of adapter proteins that interact with the
receptor. We therefore assayed the capacity of wild-type and
S332A/S334A C5aR-expressing HL-60 cells to internalize
125I-labeled C5a. As illustrated in Fig.
7, wild-type and S332A/S334A C5aRs were found
to be equally efficient at internalizing 125I-labeled C5a
in HL-60 cells. The time courses of internalization were, on average,
not significantly different. No internalization of
125I-labeled C5a was observed with mock-transfected cells,
indicating that the accumulation of radioactivity in C5aR-expressing
cells was not due to pinocytosis. Thus, although the mutations S332A and S334A impair the ability of the receptor to undergo
desensitization, they do not impair its ability to undergo
agonist-mediated internalization.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 7.
Sequestration of C5aR is independent of its
desensitization in myeloid HL-60 cells. Mock-transfected cells
(Mock) and HL-60 cells transfected with either the wild-type
C5aR (WT) or the S332A/S334A mutant receptor
(A332-334) were allowed to bind 125I-labeled
C5a, at 4 °C, and the capacity to internalize surface bound ligand
was assessed as described under "Experimental Procedures." After
different periods of incubation at 37 °C, internalization was
stopped by transferring cells into a chilled low pH buffer to remove
bound ligand that had not been internalized. Results are presented as
the mean percentage ± S.E. (n = 6) of saturably
bound 125I-labeled C5a at 4 °C that is internalized in
wild-type C5aR-expressing cells ( ) and S332A/S334A C5aR-expressing
cells ( ). For mock-transfected cells ( ), the curve represents the
amount of acid resistant radioactivity after warming divided by the
amount of radioactivity specifically bound on wild-type C5aR-expressing
cells at 4 °C.
|
|
 |
DISCUSSION |
Sequential Agonist-dependent Phosphorylation of
C5aR--
In this study, we examined the specific role of the
different serine residues of the carboxyl-terminal tail of C5aR with
respect to agonist-mediated phosphorylation and signal transduction.
The observation that the mutation S334A yields a mutant presenting a
reduced agonist-mediated phosphorylation and a complete lack of basal
phosphorylation suggests that Ser334 is a key determinant
for C5a-dependent phosphorylation and also one of the most
accessible hydroxyl residue in the absence of agonist. The mutations
S332A and S338A have individually only a limited effect on the
phosphorylation of C5aR, but either of them, in conjunction with the
mutation S334A, dramatically reduces the ability of the receptor to
undergo agonist-mediated phosphorylation (Fig. 2). This suggests that
the phosphorylation of the other serine residues is dictated by the
initial phosphorylation of either of these two pairs of serine residues
(Ser332/Ser334 or
Ser334/Ser338). This hypothesis is supported by
the observation that aspartic acid residues can substitute for
phosphorylated seryl residues at positions 332 and 334. Negative
charges at these two positions may have a "priming" function for
the recognition of the carboxyl-terminal region by acidophilic
residue-directed kinases. Alternatively, negative charges may induce a
conformational change that unmasks the other serine residues. In this
respect, a recent NMR study with the carboxyl-terminal tail of the G
protein-coupled receptor rhodopsin has revealed that a major structural
change occurs upon phosphorylation of a first residue (32). This
conformational change is further stabilized by phosphorylation of
additional residues. It is worth noting here that the negative charges
brought by the replacement of Ser332 and Ser334
by aspartic acid residues are not sufficient to promote the
phosphorylation of the remaining serine residues in the absence of C5a
binding. The results presented here support the notion that the
C5a-dependent phosphorylation proceeds sequentially,
starting on Ser334, followed by the phosphorylation of
Ser332 and/or Ser338, and then by the
phosphorylation of the other serine residues. A similar hierarchical
mechanism of phosphorylation has been previously found in the case of
rhodopsin (33), but it is not a general rule. There is no apparent
preference for any single serine residue in the case of the
1B-adrenergic receptor (34) and the CC-chemokine receptor CCR5 (35).
The Essential Role of Ser334 and Ser338 in
the Desensitization Process--
The calcium mobilization assay with
HL-60 transformants indicates that the different serine residues do not
have the same functional role. A phosphoserine at position 314, 317, 327, or 332 is not essential for the desensitization of C5aR. Although an alanine residue at position 334 results in a marked reduction of
phosphorylation, the S334A mutant continues to transduce signal with
the characteristics of a wild-type receptor, suggesting that a key
residue is still phosphorylated. This key residue is likely to be
Ser338. Indeed, despite an efficient phosphorylation, the
S338A mutant receptor has a reduced ability to desensitize the
C5a-induced calcium mobilization in undifferentiated cells. Moreover,
compared with the C5a-mediated Erk2 activity in wild-type
C5aR-expressing cells, the return to basal Erk2 activity in S338A
C5aR-expressing cells is delayed by 40-60 s. The pivotal role of
Ser338 in the desensitization process is further supported
by the observation that the S314A/S317A/S327A/S332A mutant receptor is
desensitized as efficiently as the wild-type receptor. Thus, the
phosphorylation of Ser334 and Ser338 is
apparently sufficient to confer to the receptor the ability to undergo desensitization.
In contrast to the mutations S332A/S334A, which confer to the receptor
a dominant mutant phenotype with respect to calcium mobilization in
differentiated cells, the mutation S338A has only a partial effect in
differentiated cells. Indeed, after a latency of about 30 s, the
concentration of intracellular calcium rapidly returns to basal level
as if the S338A mutant had acquired the features of a wild-type
receptor after this lag period. One possible scenario that could
explain this behavior is that the lack of phosphoseryl residue at
position 338 is compensated by the delayed phosphorylation of the
neighboring threonine residue, Thr339, by a kinase that is
not expressed or is expressed at a lower level in undifferentiated cells.
Calcium Flux and Superoxide Production in Differentiated HL-60
Cells Expressing Desensitization-deficient C5aR--
In the presence
of extracellular calcium, the stimulation of the S332A/S334A mutant
receptor expressed in differentiated HL-60 cells leads to a prolonged
calcium elevation as compared with the calcium response triggered by
activation of the wild-type C5aR. The inability of S332A/S334A
C5aR-expressing cells to rapidly attenuate the C5a-induced calcium
response is likely to result from the deficient phosphorylation of the
S332A/S334A mutant receptor inasmuch as all independent clones tested
have the same mutant phenotype. The observation that the duration of
the C5a-induced calcium response is similar for both wild-type and
S332A/S334A mutant receptors in the absence of extracellular calcium
indicates that the sustained calcium response induced by the
S332A/S334A C5aR in the presence of extracellular calcium is due to a
prolonged activation of calcium influx.
An important observation of this study is that the expression of the
desensitization defective S332A/S334A mutant in differentiated HL-60
cells leads to a significantly higher C5a-mediated production of
reactive oxygen species as compared with cells expressing only wild-type C5aRs. In the presence of extracellular calcium, the effect
of the S332A/S334A mutant receptor on superoxide release is correlated
with a sustained calcium influx. This is consistent with previous
studies indicating that calcium influx is predominantly responsible for
the activation of the respiratory burst initiated by chemoattractant
receptors (28, 29). However, additional mechanisms are likely to
control NADPH-oxidase activation because, in the absence of
extracellular calcium, cells expressing the S332A/S334A mutant still
release more superoxide despite an intracellular calcium mobilization
similar to that triggered by the wild-type C5aR. In addition to the
prolonged activation of Erk2, desensitization defective mutant
receptors are likely to support a sustained activation of several
enzymes that are essential for NADPH-oxidase activation (e.g. phospholipase A2, phospholipase D, or PI
3-kinase).
Thus, in contrast to the chemotactic response, for which
phosphorylation of chemoattractant receptors is not required (36-38), the cytotoxic activity of phagocytic cells is to some extent regulated by the ability of chemoattractant receptors to be phosphorylated and
desensitized. The extent of the increase in superoxide production remains nevertheless limited, indicating that myeloid HL-60 cells are
still able to adapt to a persistent stimulation when receptor desensitization is defective. A phosphorylation-independent mechanism of adaptation has been recently described for the termination of
G-protein-mediated responses in the case of Dictyostelium
discoideum (38). A phosphorylation-independent adaptation of the
cytotoxic activity of neutrophils is likely because the
chemoattractant-mediated activation of the NADPH-oxidase involves the
synergistic action of several signaling pathways that can be regulated
at multiple levels by inhibitory feedback loops (5, 23, 28).
In view of the results presented here and based on previous studies
(31, 39), one can predict that nonsense mutations that would truncate
the cytoplasmic domain of C5aR after Ser327 will yield
desensitization-deficient receptors. The C5a-mediated activation of
leukocytes expressing such mutants should result in an enhancement of
the respiratory burst and possibly in a prolonged induction and release
of proinflammatory mediators, such as interleukins 1, 6, and 8, and
tumor necrosis factor
(40-43). Whether this could lead to
pathophysiological disorders under circumstances of complement
activation is presently not known. So far, no naturally occurring
mutations in the cytoplasmic tail of C5aR have been reported, nor have
inflammatory diseases been shown to be associated with deficiencies in
C5aR desensitization.
Defective Desensitization and Normal Sequestration of C5aR: a
Paradox with Respect to the Current Model of GPCR
Regulation--
According to the current model for desensitization of
GPCR (see the Introduction), phosphorylation-deficient mutants should not interact with a
-arrestin protein, and thus, both
agonist-induced desensitization and sequestration should be affected.
Interestingly, although the desensitization of the C5a-mediated calcium
response and Erk2 activity by the S332A/S334A mutant receptor is
defective in undifferentiated HL-60 cells, this latter still behaves as a wild-type receptor with respect to agonist-induced sequestration. This suggests that the desensitization and the sequestration of C5aR
are two independent events in HL-60 cells. Although a phosphorylation- and
-arrestin-dependent sequestration of C5aR is not
excluded, because we have previously shown a
phosphorylation-dependent sequestration of C5aR in
pancreatic cells (30), an alternate phosphorylation- and
-arrestin-independent pathway is likely to be efficiently used by
C5aR in myeloid cells. Further work is required to determine whether
the overexpression of dominant negative forms of
-arrestin proteins
and dynamin impairs the internalization of C5aR in HL-60 cells.
Mounting evidence suggests that GPCRs are internalized by multiple
pathways depending on the cell type used. For instance, phosphorylation
of the carboxyl-terminal cytoplasmic domain of the
opioid receptor
is required for its internalization in Chinese hamster ovary cells (44)
but not in HEK293 cells (45). In COS-7 cells, the m2 muscarinic
acetylcholine receptor can be internalized via the clathrin- and
-arrestin-dependent pathway when
-arrestin proteins
are overexpressed, but a phosphorylation-dependent,
arrestin-independent pathway is preferentially used by the m2
muscarinic acetylcholine receptor in HEK-tsA201 cells (18, 19, 46).
In the case of the
2-adrenergic receptor, the G protein-coupled
receptor kinase 2-catalyzed phosphorylation and subsequent internalization of
2-adrenergic receptor has been found to be essential in the activation of the MAP kinase Erk2 (47). Furthermore, a
recent study has suggested that
-arrestin proteins recruit and
activate the tyrosine kinase c-Src, subsequently allowing the
activation of the MAP kinases Erk1 and Erk2 (48). Mutants of C5aR that
do not desensitize should weakly interact with the
-arrestin
proteins. Consequently, a receptor-
-arrestin-Src complex should not
be formed, or if it is, it should be very transient, and the activation
of Erk2 through this pathway would be expected to be decreased as
compared with cells expressing exogenous wild-type C5aR. Actually, the
nonphosphorylatable S332A/S334A mutant receptor supports a sustained
activation of Erk2, suggesting that the formation of such a complex is
not the main pathway for Erk2 activation. The sustained activation of
Erk2 most likely results from the higher capacity of
nonphosphorylatable mutants to mobilize calcium and consequently to
activate PKC isoforms. The finding that C5a-mediated MAP kinase
activation is dramatically reduced by PKC inhibitors in HEK293 cells
strongly supports this hypothesis (49). Presently, the involvement of a
phosphorylation-independent adapter protein that would recruit a
Src-like protein and target the receptor to the endocytic pathway
cannot be excluded. Both mechanisms could be functionally redundant in
myeloid cells.
Conclusions--
In summary, the present study reveals that the
agonist-mediated phosphorylation of C5aR is sequential and requires the
initial phosphorylation of two serine pairs
(Ser332/Ser334 or
Ser334/Ser338). Although all serine residues of
the carboxyl-terminal tail are phosphorylated upon C5a addition, only
two of these serine residues, namely Ser334 and
Ser338, are sufficient for receptor desensitization. To our
knowledge, this is the first demonstration that the
chemoattractant-induced NADPH-oxidase activity is to some extent
controlled by the capacity of chemoattractant receptors to rapidly
desensitize. This may explain why chemoattractant receptors have
variable ability to trigger superoxide production despite a coupling to
the same pool of heterotrimeric Gi2 proteins. In addition
to a higher production of superoxide, a nondesensitized C5aR is likely
to induce an increased synthesis and release of inflammatory mediators.
It is therefore reasonable to hypothesize that defects in
chemoattractant receptor desensitization can have pathophysiological consequences.
 |
FOOTNOTES |
*
This work was supported by research grants from the CNRS,
the Commissariat à l'Energie Atomique, and the Université
Joseph-Fourier-Faculté de Médecine.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Supported by a fellowship from the Direction Générale
de l'Armement.
§
To whom correspondence should be addressed. Tel.: 33-476-88-31-38;
Fax: 33-476-88-51-85; E-mail: fboulay@cea.fr.
 |
ABBREVIATIONS |
The abbreviations used are:
C5a, human
complement 5a;
C5aR, C5a receptor;
GPCR, G protein-coupled receptor;
PKC, protein kinase C;
fMLFK, N-formyl-Met-Leu-Phe-Lys-OH;
Bt2cAMP, N6,O-2'-dibutyryl adenosine 3',5'
cyclic monophosphate;
Erk, extracellular signal-regulated kinase;
MAP, mitogen-activated protein;
PMA, phorbol 12-myristate 13-acetate.
 |
REFERENCES |
| 1.
|
Ye, R.,
and Boulay, F.
(1997)
Adv. Pharmacol.
39,
221-289
|
| 2.
|
Bokoch, G. M.
(1995)
Blood
86,
1649-1660[Free Full Text]
|
| 3.
|
Stephens, L.,
Eguinoa, A.,
Corey, S.,
Jackson, T.,
and Hawkins, P. T.
(1993)
EMBO J.
12,
2265-2273[Medline]
[Order article via Infotrieve]
|
| 4.
|
Alemany, R.,
Meyer zu Heringdorf, D.,
van Koppen, C. J.,
and Jakobs, K. H.
(1999)
J. Biol. Chem.
274,
3994-3999[Abstract/Free Full Text]
|
| 5.
|
Babior, B. M.
(1995)
Curr. Opin. Hematol.
2,
55-60[Medline]
[Order article via Infotrieve]
|
| 6.
|
el Benna, J.,
Faust, L. P.,
and Babior, B. M.
(1994)
J. Biol. Chem.
269,
23431-23436[Abstract/Free Full Text]
|
| 7.
|
el Benna, J.,
Faust, L. P.,
Johnson, J. L.,
and Babior, B. M.
(1996)
J. Biol. Chem.
271,
6374-6378[Abstract/Free Full Text]
|
| 8.
|
Faust, L. P.,
El Benna, J.,
Babior, B. M.,
and Chanock, S. J.
(1995)
J. Clin. Invest.
96,
1499-1505
|
| 9.
|
Dohlman, H. G.,
Thorner, J.,
Caron, M.,
and Lefkowitz, R. J.
(1991)
Annu. Rev. Biochem.
60,
653-688[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Lefkowitz, R. J.
(1998)
J. Biol. Chem.
273,
18677-18680[Free Full Text]
|
| 11.
|
Wilden, U.,
Hall, S. W.,
and Kühn, H.
(1986)
Proc. Natl. Acad. Sci. U. S. A.
83,
1174-1178[Abstract/Free Full Text]
|
| 12.
|
Dolph, P. J.,
Ranganathan, R.,
Colley, N. J.,
Hardy, R. W.,
Socolich, M.,
and Zuker, C. S.
(1993)
Science
260,
1910-1916[Abstract/Free Full Text]
|
| 13.
|
Lohse, M. J.,
Benovic, J. L.,
Codina, J.,
Caron, M. G.,
and Lefkowitz, R. J.
(1990)
Science
248,
1547-1550[Abstract/Free Full Text]
|
| 14.
|
Goodman, O. B.,
Krupnick, J. G. J.,
Santini, F.,
Gurevich, V. V.,
Penn, R. B.,
Gagnon, A. W.,
Keen, J. H.,
and Benovic, J. L.
(1996)
Nature
383,
447-450[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Ferguson, S. S. G.,
Downey, W. E., III,
Colapietro, A.-M.,
Barak, L. S.,
Ménard, L.,
and Caron, M. G.
(1996)
Science
271,
363-366[Abstract]
|
| 16.
|
Damke, H.,
Baba, T.,
Warnock, D. E.,
and Schmid, S. L.
(1994)
J. Cell Biol.
127,
915-934[Abstract/Free Full Text]
|
| 17.
|
Zhang, J.,
Ferguson, S. S. G.,
Barak, L. S.,
Ménard, L.,
and Caron, M. G.
(1996)
J. Biol. Chem.
271,
18302-18305[Abstract/Free Full Text]
|
| 18.
|
Pals-Rylaarsdam, R.,
Gurevich, V. V.,
Lee, K. B.,
Ptasienski, J.,
Benovic, J. L.,
and Hosey, M. M.
(1997)
J. Biol. Chem.
272,
23682-23689[Abstract/Free Full Text]
|
| 19.
|
Vögler, O.,
Nolte, B.,
Voss, M.,
Schmidt, M.,
Jakobs, K. H.,
and van Koppen, C. J.
(1999)
J. Biol. Chem.
274,
12333-12338[Abstract/Free Full Text]
|
| 20.
|
Tardif, M.,
Mery, L.,
Brouchon, L.,
and Boulay, F.
(1993)
J. Immunol.
150,
3534-3545[Abstract]
|
| 21.
|
Ali, H.,
Richardson, R. M.,
Tomhave, E. D.,
Didsbury, J. R.,
and Snyderman, R.
(1993)
J. Biol. Chem.
268,
24247-24254[Abstract/Free Full Text]
|
| 22.
|
Giannini, E.,
Brouchon, L.,
and Boulay, F.
(1995)
J. Biol. Chem.
270,
19166-19172[Abstract/Free Full Text]
|
| 23.
|
Tardif, M.,
Rabiet, M.-J.,
Christophe, T.,
Milcent, M. D.,
and Boulay, F.
(1998)
J. Immunol.
161,
6885-6895[Abstract/Free Full Text]
|
| 24.
|
Mery, L.,
and Boulay, F.
(1994)
J. Biol. Chem.
269,
3457-3463[Abstract/Free Full Text]
|
| 25.
|
Zhen, L.,
King, A. A. J.,
Xiao, Y.,
Chanock, S. J.,
Orkin, S. H.,
and Dinauer, M. C.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
9832-9836[Abstract/Free Full Text]
|
| 26.
|
Boulay, F.,
Mery, L.,
Tardif, M.,
Brouchon, L.,
and Vignais, P.
(1991)
Biochemistry
30,
2993-2999[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Bühl, A. M.,
Avdi, N.,
Worthen, G. S.,
and Johnson, G. L.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
9190-9194[Abstract/Free Full Text]
|
| 28.
|
Foyouzi-Youssefi, R.,
Petersson, F.,
Lew, D. P.,
Krause, K.-H.,
and Nüsse, O.
(1997)
Biochem. J.
322,
709-718
|
| 29.
|
Bei, L.,
Hu, T.,
Qian, Z.,
and Shen, X.
(1998)
Biochim. Biophys. Acta
1404,
475-483[Medline]
[Order article via Infotrieve]
|
| 30.
|
Naik, N.,
Giannini, E.,
Brouchon, L.,
and Boulay, F.
(1997)
J. Cell Sci.
110,
2381-2390[Abstract]
|
| 31.
|
Bock, D.,
Martin, U.,
Gärtner, S.,
Rheinheimer, C.,
Raffetseder, C.,
Raffetseder, U.,
Arseniev, L.,
Barker, M. D.,
Monk, P. N.,
Bautsch, W.,
Köhl, J.,
and Klos, A.
(1997)
Eur. J. Immunol.
27,
1522-1529[Medline]
[Order article via Infotrieve]
|
| 32.
|
Dorey, M.,
Hargrave, P. A.,
McDowell, J. H.,
Arendt, A.,
Vogt, T.,
Bhawsar, N.,
Albert, A. D.,
and Yeagle, P. L.
(1999)
Biochim. Biophys. Acta
1416,
217-224[Medline]
[Order article via Infotrieve]
|
| 33.
|
Ohguro, H.,
Palczewski, K.,
Ericsson, L. H.,
Walsh, K. A.,
and Johnson, R. S.
(1993)
Biochemistry
32,
5718-5724[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Diviani, D.,
Lattion, A.-L.,
and Cotecchia, S.
(1997)
J. Biol. Chem.
272,
28712-28719[Abstract/Free Full Text]
|
| 35.
|
Oppermann, M.,
Mack, M.,
Proudfoot, A. E. I.,
and Olbrich, H.
(1999)
J. Biol. Chem.
274,
8875-8885[Abstract/Free Full Text]
|
| 36.
|
Hsu, M. H.,
Chiang, S. C.,
Ye, R. D.,
and Prossnitz, E. R.
(1997)
J. Biol. Chem.
272,
29426-29429[Abstract/Free Full Text]
|
| 37.
|
Arai, H.,
Monteclaro, F. S.,
Tsou, C.-L.,
Franci, C.,
and Charo, I. F.
(1997)
J. Biol. Chem.
272,
25037-25042[Abstract/Free Full Text]
|
| 38.
|
Kim, J.-Y.,
Soede, R. D.,
Schaap, P.,
Valkema, R.,
Borleis, J. A.,
van Haastert, P. J. M.,
Devreotes, P. N.,
and Hereld, D.
(1999)
J. Biol. Chem.
272,
27313-27318[Abstract/Free Full Text]
|
| 39.
|
Klos, A.,
Matje, C.,
Rheinheimer, C.,
Bautsch, W.,
Köhl, J.,
Martin, U.,
and Burg, M.
(1994)
FEBS Lett.
344,
79-82[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Montz, H.,
Koch, K.-C.,
Zierz, R.,
and Götze, O.
(1991)
Immunology
74,
373-379[Medline]
[Order article via Infotrieve]
|
| 41.
|
Ember, J. A.,
Sanderson, S. D.,
Hugli, T. E.,
and Morgan, E. L.
(1994)
Am. J. Pathol.
144,
393-403[Abstract]
|
| 42.
|
Scholz, W.,
McClurg, M. R.,
Cardenas, G. J.,
Smith, M.,
Noonan, D. J.,
Hugli, T. E.,
and Morgan, E. L.
(1990)
Clin. Immunol. Immunopathol.
57,
297-307[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Okusawa, S.,
Yancey, K. B.,
van der Meer, J. W.,
Endres, S.,
Lonnemann, G.,
Hefter, K.,
Frank, M. M.,
Burke, J. F.,
Dinarello, C. A.,
and Gelfand, J. A.
(1988)
J. Exp. Med.
168,
443-448[Abstract/Free Full Text]
|
| 44.
|
Trapaidze, N.,
Keith, D. E.,
Cvejic, S.,
Evans, C. J.,
and Devi, L. A.
(1996)
J. Biol. Chem.
271,
29273-29285
|
| 45.
|
Murray, S. R.,
Evans, C. J.,
and von Zastrow, M.
(1998)
J. Biol. Chem.
273,
24987-24991[Abstract/Free Full Text]
|
| 46.
|
Vögler, O.,
Bogatkewitsch, G. S.,
Wriske, C.,
Krummenerl, P.,
Jakobs, K. H.,
and van Koppen, C. J.
(1998)
J. Biol. Chem.
273,
12155-12160[Abstract/Free Full Text]
|
| 47.
|
Daaka, Y.,
Luttrell, L. M.,
Ahn, S.,
Della Rocca, G. J.,
Ferguson, S. S. G.,
Caron, M. G.,
and Lefkowitz, R. J.
(1998)
J. Biol. Chem.
273,
685-688[Abstract/Free Full Text]
|
| 48.
|
Luttrell, L. M.,
Ferguson, S. S. G.,
Daaka, Y.,
Miller, W. E.,
Maudsley, S.,
Della Rocca, G. J.,
Lin, F.-T.,
Kawakatsu, H.,
Owada, K.,
Luttrell, D. K.,
Caron, M. G.,
and Lefkowitz, R. J.
(1999)
Science
283,
655-661[Abstract/Free Full Text]
|
| 49.
|
Bühl, A. M.,
Osawa, S.,
and Johnson, G. L.
(1995)
J. Biol. Chem.
270,
19828-19832[Abstract/Free Full Text]
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg